Acadia Healthcare (NASDAQ:ACHC) Price Target Raised to $27.00

Acadia Healthcare (NASDAQ:ACHC) had its target price boosted by UBS Group from $24.00 to $27.00 in a research report report published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Other research analysts have also recently issued reports about the company. Royal Bank Of Canada increased their price target on Acadia Healthcare from $17.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday. Jefferies Financial Group cut Acadia Healthcare to a “hold” rating in a report on Thursday, January 22nd. Raymond James Financial reissued an “outperform” rating and set a $25.00 price target on shares of Acadia Healthcare in a research note on Thursday. Guggenheim reduced their price target on Acadia Healthcare from $27.00 to $22.00 and set a “buy” rating on the stock in a report on Monday, February 23rd. Finally, Bank of America lowered shares of Acadia Healthcare from a “neutral” rating to an “underperform” rating and dropped their price objective for the company from $21.50 to $13.00 in a report on Wednesday, December 3rd. Seven equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Acadia Healthcare has a consensus rating of “Hold” and an average price target of $20.69.

Acadia Healthcare Stock Up 5.2%

ACHC stock opened at $23.44 on Thursday. The firm has a 50-day moving average price of $14.82 and a 200-day moving average price of $18.56. Acadia Healthcare has a 12 month low of $11.43 and a 12 month high of $33.58. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $2.16 billion, a P/E ratio of -1.92, a price-to-earnings-growth ratio of 8.06 and a beta of 0.89.

Acadia Healthcare (NASDAQ:ACHC) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. The business had revenue of $821.46 million during the quarter, compared to analysts’ expectations of $800.10 million. Acadia Healthcare had a negative net margin of 33.29% and a positive return on equity of 6.53%. The firm’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.64 EPS. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS. As a group, equities research analysts anticipate that Acadia Healthcare will post 3.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Acadia Healthcare

A number of hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP boosted its holdings in Acadia Healthcare by 24.9% in the fourth quarter. Wellington Management Group LLP now owns 11,774,308 shares of the company’s stock valued at $167,077,000 after acquiring an additional 2,350,760 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Acadia Healthcare by 7.8% in the 3rd quarter. Vanguard Group Inc. now owns 9,417,045 shares of the company’s stock worth $233,166,000 after purchasing an additional 681,278 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Acadia Healthcare by 417.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 4,728,613 shares of the company’s stock worth $67,099,000 after purchasing an additional 3,815,471 shares during the period. Abrams Bison Investments LLC boosted its stake in shares of Acadia Healthcare by 22.3% in the 3rd quarter. Abrams Bison Investments LLC now owns 4,380,000 shares of the company’s stock valued at $108,449,000 after purchasing an additional 800,000 shares during the last quarter. Finally, UBS Group AG increased its position in shares of Acadia Healthcare by 8.8% during the third quarter. UBS Group AG now owns 4,336,698 shares of the company’s stock worth $107,377,000 after buying an additional 350,484 shares during the period.

More Acadia Healthcare News

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Q4 revenue topped estimates and EPS beat consensus, driving a strong intraday jump; management provided FY2026 and Q1 2026 guidance that gave investors a clearer outlook. Acadia Healthcare’s (NASDAQ:ACHC) Q4 CY2025 Sales Top Estimates, Stock Jumps 10.8%
• Positive Sentiment: The company posted its Q4 earnings presentation and materials, helping investors parse revenue mix, margin drivers and the path to management’s FY26 targets. Acadia Healthcare Company, Inc. 2025 Q4 – Results – Earnings Call Presentation
• Positive Sentiment: Multiple brokerages raised price targets and maintain buy/outperform stances—RBC to $28 (outperform), UBS to $27 (buy) and TD Cowen to $24 (buy)—which increases buy-side conviction and likely supported the rally. Benzinga: Analyst Price-Target Updates
• Positive Sentiment: Analysts and commentary highlighted improving execution and embedded EBITDA opportunities under returning management, reinforcing the view that operational fixes could restore profitability. TipRanks: Buy Rating on Improving Execution
• Neutral Sentiment: Aggregated analyst coverage: a Benzinga deep-dive summarizes 17 analyst ratings and consensus perspectives — useful for context on how Street expectations are shifting but not a single catalyst. Acadia Healthcare Co Stock: A Deep Dive Into Analyst Perspectives (17 Ratings)
• Negative Sentiment: Short interest remains very large (~32.45M shares as of mid‑Feb, ~35.9% of float) with a ~7.3 days-to-cover ratio — this high short position increases the risk of volatile trading, squeezes, or pressure if execution disappoints. (short-interest reports summarized in filings and market data)

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.